Användning av cookies

Lunds universitet använder cookies för att se till att webbplatsen fungerar korrekt och för att förbättra din upplevelse.

Läs mer i vår cookiepolicy

Sökresultat

Filtrera

Nollställ filter

Filtyp

Din sökning på "*" gav 535084 sökträffar

Esculetin (dihydroxycoumarin) inhibits the production of matrix metalloproteinases in cartilage explants, and oral administration of its prodrug, CPA-926, suppresses cartilage destruction in rabbit experimental osteoarthritis

Objective. To investigate the in vitro effects of 6,7-dihydroxycoumarin (esculetin) on the production of matrix metalloproteinases (MMP) in rabbit articular cartilage, and the in vivo effects of orally administered CPA-926, a prodrug of esculetin, on cartilage destruction in rabbit experimental osteoarthritis (OA). Methods. In vitro studies were performed using rabbit articular cartilage explants.

Risk Aversion and Guanxi Activities : A Behavioral Analysis of CEOs in China

In China, the strategic use of personal relationships is pervasive in transactions with government authorities as well as in inter-firm relations. Explanations as to when and why firms rely on guanxi emphasize a close link between organizational resources, environment and corporate strategic choices. Our study shifts attention to the importance of CEO preferences, specifically risk aversion, and s

Individual patient data meta-analysis of trials investigating the effectiveness of intra-articular glucocorticoid injections in patients with knee or hip osteoarthritis : an OA Trial Bank protocol for a systematic review.

Based on small to moderate effect sizes for the wide range of symptomatic treatments in osteoarthritis (OA), and on the heterogeneity of OA patients, treatment guidelines for OA have stressed the need for research on clinical predictors of response to different treatments. A meta-analysis to quantify the effect modified by the predictors using individual patient data (IPD) is suggested. The initia

OARSI recommendations for the management of hip and knee osteoarthritis. Part III : Changes in evidence following systematic cumulative update of research published through January 2009.

Objective: To update evidence for available therapies in the treatment of hip and knee osteoarthritis (OA) and to examine whether research evidence has changed from 31 January 2006 to 31 January 2009. Methods: A systematic literature search was undertaken using MEDLINE, EMBASE, CINAHL, AMED, Science Citation Index and the Cochrane Library. The quality of studies was assessed. Effect sizes (ESs) an

What are the outcomes after joint replacement?

Total hip replacement (THR) is an effective intervention with a good cost/benefit ratio. Worldwide, each year it brings relief in the form of improved function and decreased pain to at least half a million patients with severe osteoarthritis (OA). Since the introduction by Charnley more than 30 years ago, the basic concept remains much the same, but with a multitude of changes in details of surgic

OARSI recommendations for the management of hip and knee osteoarthritis, Part II : OARSI evidence-based, expert consensus guidelines

Purpose: To develop concise, patient-focussed, up to date, evidence-based, expert consensus recommendations for the management of hip and knee osteoarthritis (OA), which are adaptable and designed to assist physicians and allied health care professionals in general and specialist practise throughout the world. Methods: Sixteen experts from four medical disciplines (primary care, rheumatology, orth